Holen Sie sich die Stockscreener-App
0.9238
12.02%
-0.1262
Celularity Inc Aktie (CELU) Neueste Nachrichten
A $706K Q2 profit accompanies a cash warning at Celularity (CELU). - Stock Titan
A $3M trust note gets a $1.50 conversion price in Celularity (CELU)'s financing. - Stock Titan
A profit, but not enough cash for the next 12 months: Celularity (NASDAQ: CELU) says it needs financing. - Stock Titan
A trust can name two of Celularity's (CELU) five directors under a financing deal. - Stock Titan
Form 8K Celularity Inc For: 28 September By Investing.com - Investing.com Nigeria
Form 8K Celularity Inc For: 28 September By Investing.com - Investing.com India
Form 8K Celularity Inc For: 28 September By Investing.com - Investing.com UK
Celularity Secures New Convertible Note Financing and Board Shift - TipRanks
Celularity Raises Up to $25M Secured Convertible Notes, Adds Board Rights, Settles With Helena - TradingView
Celularity Director Philip Barach Updates Convertible Notes and Warrants, Acquires New Securities - Kalkine Media
Form 4 Celularity Inc For: 25 September By Investing.com - Investing.com Canada
Form 4 Celularity Inc For: 25 September - Investing.com India
A note’s share-conversion price fell from $1.66 to $1.50 as a Celularity (CELU) 10% owner bought more notes. - Stock Titan
1,177,000 warrants came with a Celularity (CELU) note purchase by a 10% owner's trust. - Stock Titan
Form 4 Celularity Inc For: 25 September By Investing.com - Investing.com UK
Celularity Regains Nasdaq Compliance on Bid Price and Market Value Rules - Minichart
Celularity and MuseCell Innovations Strike New Jersey Manufacturing Deal Worth Up to $300 Million - BioBuzz
Celularity and MuseCell Innovations strike US manufacturing deal with potential $300m upside & 200 jobs - Indian Pharma Post
Celularity Inc (CELUW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Celularity Manufacturing Deal Could Bring $300 Million, 200 Jobs to Florham Park - Morris Focus
Financial Forecasts News & Analysis - TechStock²
Celularity Partners with MuseCell Innovations to Manufacture Allogeneic Cell Therapy Products in the US - BioPharm International
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform - Investing News Network
Why Is Celularity Stock Gaining Thursday? - Benzinga
Florham Park Facility at Center of Cell Therapy Manufacturing Deal Worth Up to $300 Million - centraljersey.com
Celularity and MuseCell Innovations announce manufacturing collaboration - ROI-NJ
$Celularity (CELU.US)$ It's 100% happening, guys - Moomoo
Singapore's MuseCell Innovations announces manufacturing collaboration with Celularity in US - BioSpectrum Asia
Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform - tradingview.com
Celularity to manufacture Dezawa MuseCells for MuseCell Innovations By Investing.com - Investing.com India
Celularity to manufacture Dezawa MuseCells for MuseCell Innovations By Investing.com - Investing.com UK
Celularity (NASDAQ:CELU): Why Is It in Focus After It provided a fresh Nasdaq listing-compliance update? - Kalkine Media
Celularity Provides Update Regarding Nasdaq Listing Compliance - The Manila Times
Celularity Inc. Receives Nasdaq Notice for Late Quarterly Filings, Working to Regain Compliance - Quiver Quantitative
Celularity (CELU) Latest Quarter: The Bottom-Line Figure Outpaces Its Comparison in the Current Update; Shares Move Lower 2.01% on the DayDividend Earnings Report - vinanet.vn
Celularity (CELU) Technicals: Declines 2.01% to $0.80 in the Current Update; Key Range: Support at $0.76 and Resistance at $0.84 Frame the Range on the DayWide Range Bar - dars.gov.et
Celularity (CELU) Levels: Finishes 1.41% Down at $0.77 in Latest Trading; Range Check: the Near-Term Reference Band Stretches From $0.73 to $0.81 under the Current SnapshotPrice Momentum Stocks - vinanet.vn
Celularity (CELU) Levels: Finishes 1.41% Down at $0.77 in Latest Trading; Range Check: the Near-Term Reference Band Stretches From $0.73 to $0.81 under the Current SnapshotVolume Weighted Price - dars.gov.et
Celularity (CELU) Earnings Snapshot: The EPS Result Is Above Expectation on the Day; Share Move: Shares Move 5.89% Higher in the Current UpdateEPS Surprise History - vinanet.vn
Celularity (CELU) Earnings Snapshot: The EPS Result Is Above Expectation on the Day; Share Move: Shares Move 5.89% Higher in the Current UpdateWeak Earnings Momentum - dars.gov.et
Celularity (CELU) Earnings Snapshot: The EPS Result Is Above Expectation on the Day; Share Move: Shares Move 5.89% Higher in the Current UpdateMargin Expansion Trends - dars.gov.et
Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition - TipRanks
NEXGEL Q2 2026: Revenue $3.69M, Net Loss $2.87M as Company Transitions Post-Acquisition - TradingView
Celularity Delays Quarterly SEC Filing - TipRanks
Celularity (CELU) delays June 2026 10-Q filing amid liquidity and staffing strain - Stock Titan
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy - Stock Titan
CELU Q4 2025 Earnings Narrower Loss Beats Estimates by 4444 as Shares Rise 072Market Intelligence - vinanet.vn
Celularity (CELU) Slips 2% as Stock Holds Between $0.66 Support and $0.72 ResistanceFast Moving Stocks - dars.gov.et
Celularity Announces Sudden Exit of Chief Commercial Officer - The Globe and Mail
Celularity Inc. Files Form 8-K as Emerging Growth Company on NASDAQ CELU Shares - minichart.com.sg
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):